The study showed Cerebiome's ability to balance the gut microbiota and decrease the abundance of bacterial genera which are associated with anxiety symptoms
Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome on the gut microbiota of individuals with mild anxiety.
Cerebiome is a proprietary combination of L. helveticus Rosell-52 and B. longum Rosell-175. Previous studies have highlighted eight mechanisms of action on the gut-brain axis.
The positive influence of Cerebiome on the gut microbiota of individuals with mild anxiety was demonstrated for the first time by using a dynamic microbiome model [De Oliveira et al. 2023]. The Simulator of the Human Intestinal Microbial Ecosystem (SHIME) model is a dynamic replica of the human gastrointestinal tract, which allows probiotic passage through the stomach, small intestine, and colon of anxious donors.
“The SHIME study reinforces our commitment to physicians and patients. By contributing to science, we are also building a more scientific base for the proper use of our products, while helping thousands of Brazilians who suffer from occasional or mild anxiety symptoms,'' explained Márcio Castanha, Commercial Vice-President at Apsen.
“We are very pleased with our ever-flourishing collaboration with Apsen, a partner with whom we share a similar scientific philosophy and work ethic. Our cooperation over the years has garnered the introduction of innovative probiotic solutions for the benefit of all Brazilians,” noted Edwing Koc, Sales Manager, responsible for the Latin America region at Lallemand Health Solutions.
Knowledge of the microbiota signature in patients with mild anxiety disorders provides a promising direction for the prevention of mental illness prevention
The SHIME study showed for the first time Cerebiome's ability to balance the gut microbiota and decrease the abundance of bacterial genera which are associated with anxiety symptoms and inflammation (Lachnospira and Escheria-Shigella). In addition, an increase of GABA production was observed after 14 days of probiotic intake, when compared to the control period. GABA is an important neurotransmitter in the central nervous system, for which a deficiency is usually observed in individuals with anxiety-like behaviours.
Another finding reveals that the probiotic intake significantly decreased ammonia (NH4+) production, when compared to the control period. Ammonia is observed in excess in individuals with motor and cognitive dysfunctions. This new publication also confirms that Cerebiome strains survive the gastrointestinal passage, significantly increase the SCFAs and exerts a positive effect on cytokine secretion in the gut.
These findings confirm Cerebiome correlation on the microbiome-gut-brain axis and its promising mental health applications.
According to Dr Katia Sivieri, researcher responsible for conducting the study, “knowledge of the microbiota signature in patients with mild anxiety disorders provides a promising direction for the prevention of mental illness prevention and opens a new perspective on the use of psychobiotics as a therapeutic intervention.”
Lallemand’s documented probiotic Cerebiome for the gut-brain axis is offered in exclusivity by Apsen to the Brazilian market. Cerebiome is the first probiotic formulation for the brain-gut axis on the Brazilian market, with approved health claims by the Brazilian Health Authorities (ANVISA).